Treating Monoclonal Antibody Release in UK Patients with No Antibody Response • Protecting Children’s Health


Eligible COVID patients in UK hospitals are offered monoclonal antibody treatment ronapreve, a combination of two monoclonal antibodies that work by binding to two different protein sites on the SARS-CoV-2 spike and secreting the ability of the virus to infect cells.

Defender experienced censorship on many social channels. Be sure to keep in touch with news that matters subscribe to our top news of the day. It’s free.

Suitable patients with COVID-19 in UK hospitals that have not developed an antibody response against SARS-CoV-2 will offer monoclonal antibody treatment ronapreve from this week, the government has announced.

The drug is a combination of two monoclonal antibodies (casirivimab and imdevimab), which work by binding to two different SARS-CoV-2 sites. protein on the spike and eliminate the ability of the virus to infect cells. This is the first neutralizing the drug antibody specifically designed to treat COVID-19 approved by the Medicines and Healthcare Products Regulatory Agency (as of August 2021).

Ronapreve will be given to patients without antibodies – who must be age 50 or older, or aged 12 to 49 and considered immunocompromised – by drip. The government says they have secured enough supply for National Health Service patients across the country and that antibody testing will be used to determine which patients are eligible.

England’s health secretary, Sajid Javid, said:

“We are ensuring innovative treatment for our most vulnerable patients in hospitals across the UK… The UK is leading the world in identifying and launching life-saving medicines, especially for COVID-19, and will continue our vital work to find the best treatments available to save lives and protect the NHS. “

Japan was the first country to issue a drug license in July after a phase III trial reported that it reduced hospital admissions or deaths by 70% in high -risk undiagnosed patients. Treatment was administered by injection or infusion and was found to reduce the duration of symptoms to four days.

The combination of casirivimab and imdevimab was also tested as part of the UK Rehabilitation trial, which concluded that it reduced the risk of death when given to hospitalized patients with severe COVID-19 unattended. in the natural antibody response to the virus.

Originally published on The BMJ September 21, 2021, written by Elisabeth Mahase, copy here under CC BY NC license terms.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *